摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,6-Dimethyl-3-methylthio-1-(pyrid-2-yl)-4,5,6,7-tetrahydrobenzo[c]thiophen-4-one | 207306-63-6

中文名称
——
中文别名
——
英文名称
6,6-Dimethyl-3-methylthio-1-(pyrid-2-yl)-4,5,6,7-tetrahydrobenzo[c]thiophen-4-one
英文别名
6,6-Dimethyl-3-methylsulfanyl-1-pyridin-2-yl-6,7-dihydro-5H-benzo[c]thiophen-4-one;6,6-dimethyl-3-methylsulfanyl-1-pyridin-2-yl-5,7-dihydro-2-benzothiophen-4-one
6,6-Dimethyl-3-methylthio-1-(pyrid-2-yl)-4,5,6,7-tetrahydrobenzo[c]thiophen-4-one化学式
CAS
207306-63-6
化学式
C16H17NOS2
mdl
——
分子量
303.449
InChiKey
ZZTJJGWSKYVZIG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    83.5
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6,6-Dimethyl-3-methylthio-1-(pyrid-2-yl)-4,5,6,7-tetrahydrobenzo[c]thiophen-4-one间氯过氧苯甲酸 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 以79%的产率得到6,6-dimethyl-3-methanesulphinyl-1-(pyridin-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one
    参考文献:
    名称:
    6,7-Dihydro-2-benzothiophen-4(5H)-ones:  A Novel Class of GABA-A α5 Receptor Inverse Agonists
    摘要:
    Nonselective inverse agonists at the benzodiazepine binding site on the GABA-A chloride ion channel enhance cognitive performance in animals but cannot be used in the treatment of cognitive disorders because of anxiogenic and convulsant side effects. We have identified a novel series of GABA-A alpha5 receptor ligands during our search for alpha5 receptor inverse agonists as potential cognition enhancers. In particular, 6,6-dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro- 2-benzothiophen-4(5H-)-one (26) has been identified as a functionally selective GABA-A alpha5 inverse agonist.
    DOI:
    10.1021/jm010471b
  • 作为产物:
    描述:
    1-bromo-6,6-dimethyl-3-methanesulfonyl-6,7-dihydro-2-benzothiophen-4(5H)-one 在 四(三苯基膦)钯 作用下, 以 四氢呋喃1,4-二氧六环 为溶剂, 反应 90.0h, 生成 6,6-Dimethyl-3-methylthio-1-(pyrid-2-yl)-4,5,6,7-tetrahydrobenzo[c]thiophen-4-one
    参考文献:
    名称:
    6,7-Dihydro-2-benzothiophen-4(5H)-ones:  A Novel Class of GABA-A α5 Receptor Inverse Agonists
    摘要:
    Nonselective inverse agonists at the benzodiazepine binding site on the GABA-A chloride ion channel enhance cognitive performance in animals but cannot be used in the treatment of cognitive disorders because of anxiogenic and convulsant side effects. We have identified a novel series of GABA-A alpha5 receptor ligands during our search for alpha5 receptor inverse agonists as potential cognition enhancers. In particular, 6,6-dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro- 2-benzothiophen-4(5H-)-one (26) has been identified as a functionally selective GABA-A alpha5 inverse agonist.
    DOI:
    10.1021/jm010471b
点击查看最新优质反应信息

文献信息

  • Thienycyclohexanone derivatives as ligands of the GABAA &agr;5 receptor subtype
    申请人:Merck Sharp & Dohme Limited
    公开号:US06262103B1
    公开(公告)日:2001-07-17
    A pharamceutical composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein A is C1-6alkyl, C2-6alkenyl, C2-6-alkynyl, C3-6-cycloalkyl, arylC1-6alkyl, aryl, S(O)pR1.
    一种药物组合物包括式(I)的化合物或其药用可接受的盐,其中A为C1-6烷基,C2-6烯基,C2-6炔基,C3-6环烷基,芳基C1-6烷基,芳基,S(O)pR1。
  • Substituted thienobenzisoxazole derivatives for enhancing cognition
    申请人:Merck Sharp & Dohme Limited
    公开号:US06143773A1
    公开(公告)日:2000-11-07
    The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein A is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, arylC.sub.1-6 alkyl, aryl, S(O).sub.p R.sup.1, OR.sup.1 or NR.sup.1 R.sup.12 ; B is optionally substituted 5- or 6-membered heteroaromatic ring or C(O)NR.sup.10 R.sup.11 ; R.sup.1 is hydrogen, optionally substituted C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl or C.sub.3-6 cycloalkenyl, optionally substituted aryl, arylC.sub.1-6 alkyl, arylC.sub.2-6 alkenyl or arylC.sub.2-6 alkynyl or an optionally substituted 5- or 6-membered heteroaromatic ring; R.sup.2 and R.sup.3 are hydrogen or C.sub.1-6 alkyl; R.sup.4 is hydrogen, C.sub.1-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl, aryl or CH.sub.2 (CO).sub.m NR.sup.8 R.sup.9 ; R.sup.5 is NR.sup.6 R.sup.7, C.sub.1-6 alkyl or C.sub.1-6 alkoxy; R.sup.6 is independently as defined for R.sup.4 ; R.sup.7 is aryl optionally substituted by halogen, nitro or cyano; R.sup.8 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkenyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl; arylC.sub.1-6 alkyl, arylC.sub.2-6 alkenyl or arylC.sub.2-6 alkynyl optionally substituted on the aryl ring by halogen, nitro or cyano; thiophene or pyridine; R.sup.9 is C.sub.1-6 alkyl; C.sub.2- alkenyl; C.sub.2-6 alkynyl; or phenyl optionally substituted by one, two or three substituents independently chosen from halogen, CF.sub.3, OCH.sub.3, nitro and cyano; R.sup.10 and R.sup.11 are individually hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or C.sub.3-8 cycloalkyl or R.sup.10 and R.sup.11, together with the nitrogen atom to which they are attached, form a saturated 4 to 8 membered ring optionally containing an oxygen atom or a further nitrogen atom as a ring member, the further nitrogen atom being unsubstituted or substituted by C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl; R.sup.12 is hydrogen or C.sub.1-6 alkyl; m is zero or 1; p is zero, 1 or 2; q is 0, 1 or 2; and r is 0, 1 or 2; the preparation of these compounds, their use in enhancing cognition in disease states, particularly Alzheimer's disease, and methods of treatment using them.
    本发明提供了式(I)的化合物及其药学上可接受的盐:##STR1##其中A为C.sub.1-6烷基,C.sub.2-6烯基,C.sub.2-6炔基,C.sub.3-6环烷基,芳基C.sub.1-6烷基,芳基,S(O).sub.p R.sup.1,OR.sup.1或NR.sup.1 R.sup.12;B为可选择取代的5-或6-成员杂芳环或C(O)NR.sup.10 R.sup.11;R.sup.1为氢,可选择取代的C.sub.1-6烷基,C.sub.2-6烯基,C.sub.2-6炔基,C.sub.3-6环烷基或C.sub.3-6环烯基,可选择取代的芳基,芳基C.sub.1-6烷基,芳基C.sub.2-6烯基或芳基C.sub.2-6炔基或可选择取代的5-或6-成员杂芳环;R.sup.2和R.sup.3为氢或C.sub.1-6烷基;R.sup.4为氢,C.sub.1-8烷基,C.sub.2-8烯基,C.sub.2-8炔基,芳基或CH.sub.2(CO).sub.m NR.sup.8 R.sup.9;R.sup.5为NR.sup.6 R.sup.7,C.sub.1-6烷基或C.sub.1-6烷氧基;R.sup.6独立定义为R.sup.4;R.sup.7为芳基,可选择取代的卤素,硝基或氰基;R.sup.8为氢,C.sub.1-6烷基,C.sub.3-6环烷基,C.sub.3-6环烯基,C.sub.2-6烯基,C.sub.2-6炔基;芳基C.sub.1-6烷基,芳基C.sub.2-6烯基或芳基C.sub.2-6炔基,可选择取代的卤素,硝基或氰基的芳基环;噻吩或吡啶;R.sup.9为C.sub.1-6烷基;C.sub.2-烯基;C.sub.2-6炔基;或苯基,可选择取代为一个,两个或三个独立选择的卤素,CF.sub.3,OCH.sub.3,硝基和氰基;R.sup.10和R.sup.11分别为氢,C.sub.1-6烷基,C.sub.2-6烯基,C.sub.2-6炔基或C.sub.3-8环烷基或R.sup.10和R.sup.11,与它们连接的氮原子一起形成饱和的4到8成员环,可选择包含一个氧原子或另一个氮原子作为环成员,另一个氮原子未取代或取代为C.sub.1-4烷基,C.sub.2-4烯基或C.sub.2-4炔基;R.sup.12为氢或C.sub.1-6烷基;m为零或1;p为零,1或2;q为0,1或2;r为0,1或2;这些化合物的制备,它们在增强认知能力中的应用,特别是在疾病状态下,尤其是阿尔茨海默病中的治疗方法。
  • [EN] THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABAA alpha 5 RECEPTOR SUBTYPE<br/>[FR] DERIVES DE LA THIENYLCYCLOHEXANONE UTILISES COMME LIGANDS DU SOUS-TYPE alpha -5 DE RECEPTEUR DU GABAA
    申请人:MERCK SHARP & DOHME LIMITED
    公开号:WO1998018792A1
    公开(公告)日:1998-05-07
    (EN) The present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein A is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, arylC1-6alkyl, aryl, S(O)pR1.(FR) L'invention concerne une composition pharmaceutique contenant un composé de formule (I), dans laquelle A est alkyle C1-C6, alkényle C2-C6, alkynyle C2-C6, cycloalkyle C3-C6, arylalkyle C1-C6, aryle, S(O)pR1, ou un sel pharmaceutiquement acceptable dudit composé.
    该发明提供了一种药物组合物,包括公式(I)的化合物或其药学上可接受的盐,其中A为C1-6烷基,C2-6烯基,C2-6炔基,C3-6环烷基,芳基C1-6烷基,芳基,S(O)pR1。
  • 6,7-Dihydro-2-benzothiophen-4(5<i>H</i>)-ones:  A Novel Class of GABA-A α5 Receptor Inverse Agonists
    作者:Mark S. Chambers、John R. Atack、Frances A. Bromidge、Howard B. Broughton、Susan Cook、Gerard R. Dawson、Sarah C. Hobbs、Karen A. Maubach、Austin J. Reeve、Guy R. Seabrook、Keith Wafford、Angus M. MacLeod
    DOI:10.1021/jm010471b
    日期:2002.3.1
    Nonselective inverse agonists at the benzodiazepine binding site on the GABA-A chloride ion channel enhance cognitive performance in animals but cannot be used in the treatment of cognitive disorders because of anxiogenic and convulsant side effects. We have identified a novel series of GABA-A alpha5 receptor ligands during our search for alpha5 receptor inverse agonists as potential cognition enhancers. In particular, 6,6-dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro- 2-benzothiophen-4(5H-)-one (26) has been identified as a functionally selective GABA-A alpha5 inverse agonist.
  • THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A? $g(a)5 RECEPTOR SUBTYPE
    申请人:MERCK SHARP & DOHME LTD.
    公开号:EP0937072A1
    公开(公告)日:1999-08-25
查看更多